Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Mol Immunol. 2015 Apr 28;67(2 0 0):142–152. doi: 10.1016/j.molimm.2015.04.001

Figure 6. Applications of antibody imaging in oncology.

Figure 6

Imaging of specific biomarkers can be used to accurately locate lesions, aid in choosing a treatment, and monitor response to therapy. (A) PET imaging using the 124I-anti-PSCA minibody A11 was able to detect intratibial LAPC-9 prostate cancer xenografts with higher sensitivity and specificity than a 18F-Fluoride bone scan. (B) Response to anti-androgen treatment was monitored by visualizing reduced 124I-A11 activity in the tumors of enzalutamide-treated mice, reflecting a therapy-induced downregulation of PSCA expression. (C) The Hcc827-GR6 non-small cell lung cancer line developed resistance to gefitinib through upregulation of MET expression. PET imaging MET using a 89Zr-DFO-labeled MET-specific human minibody clearly visualized the overexpression of MET in the gefitinib-resistant tumors. (Knowles et al., 2014a; Li et al., 2014)